BIOMARIN PHAR. DL-,001 | 67.63 |
Date/Time | 02/25 / 17:35 |
Chg. / Chg.(%) | - / |
Bid | - |
Ask | - |
Open | 67.63 |
Previous Close | 66.28 |
High | 67.63 |
Low | 67.63 |
Volume [EUR] | 0.00 |
Volume [Units] | 0 |
Price fixings | 1 |
ISIN | US09061G1013 |
Security | BM8 |
Exchange | Xetra |
Type | Stock |
Exchange | Last | Volume | |
---|---|---|---|
NASDAQ | 76.8000 | ![]() |
1,189,079 |
IEX | 77.32 | ![]() |
66,065 |
Cboe US | 76.86 | ![]() |
63,171 |
Vienna Globa.. | 62.99 | ![]() |
2,825 |
TradeGate | 62.950 | ![]() |
842 |
Düsseldorf | 62.96 | ![]() |
801 |
Frankfurt | 63.2600 | ![]() |
342 |
Stuttgart | 63.280 | ![]() |
100 |
gettex | 63.500 | ![]() |
66 |
Berlin | 63.99 | ![]() |
0 |
München | 64.58 | ![]() |
0 |
Lang & Schwa.. | 63.50 | ![]() |
|
London Inter.. | 83.10 | 64 | |
Mexico | 1,700.00 | ![]() |
7 |
Xetra | 67.63 | 0 |
News
- BioMarin sinks 32% as FDA delays its hemophilia treatment
08/19/2020 / 16:23 - TeleTrader - Nasdaq turns red as pharma stocks fall
04/28/2020 / 16:48 - TeleTrader - BioMarin Enrolls First Participant in Phase 3 Trial of Vosoritide for Treatment of Children with Achondroplasia
12/12/2016 / 14:29 - GlobeNewswire - NICE Recommends BioMarin's Vimizim® (elosulfase alfa) for the Treatment of Morquio A Syndrome in England
11/23/2015 / 16:59 - GlobeNewswire